Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Assessment of Spironolactone Effects on the Prevention of Progression of Proteinuria in Chronic Kidney Diseases

Heshmatolah Shahbazian 1 , Azita Zafar Mohtashami 2 , * , Seyed Seifollah Belladi Musavi 3 , Mahnaz Danesh 3 and Gholam Reza Lashkarara 4
Authors Information
1 Professor of Nephrology, Diabetes and CKD Research Centers, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, IR Iran
2 Assisstant Professor of Nephrology, Department of Internal Medicine, Shaheed Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, IR Iran
3 Assisstant Professor of Nephrology, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, IR Iran
4 General Physician, MPH, Lorestan University of Medical Sciences, Khorramabad, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 01, 2016, 11 (2); e25682
  • Published Online: March 14, 2016
  • Article Type: Research Article
  • Received: December 2, 2014
  • Revised: February 1, 2015
  • Accepted: April 15, 2015
  • DOI: 10.17795/jjnpp-25682

To Cite: Shahbazian H, Zafar Mohtashami A, Belladi Musavi S S, Danesh M, Reza Lashkarara G. Assessment of Spironolactone Effects on the Prevention of Progression of Proteinuria in Chronic Kidney Diseases, Jundishapur J Nat Pharm Prod. 2016 ; 11(2):e25682. doi: 10.17795/jjnpp-25682.

Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. KDIGO . Clinical_practice_guidelines. 2012;
  • 2. KDIGO . Guidelines_CKD. 2012;
  • 3. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2013; 14: 46[DOI][PubMed]
  • 4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41(1): 1-12[DOI][PubMed]
  • 5. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17): 2038-47[DOI][PubMed]
  • 6. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005; 20(12): 2587-93[DOI][PubMed]
  • 7. Denker B, Lin J. Harrison's Principles of Internal Medicine. 2012;
  • 8. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006; 17(11): 2974-84[DOI][PubMed]
  • 9. Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant. 2007; 22 Suppl 9-30[DOI][PubMed]
  • 10. Staples A, Wong C. Risk factors for progression of chronic kidney disease. Curr Opin Pediatr. 2010; 22(2): 161-9[DOI][PubMed]
  • 11. Thilly N, Boini S, Kessler M, Briancon S, Frimat L. Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale). Nephrol Dial Transplant. 2009; 24(3): 934-9[DOI][PubMed]
  • 12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12): 861-9[DOI][PubMed]
  • 13. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001; 135(2): 73-87[PubMed]
  • 14. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ. 1999; 319(7201): 24-5[PubMed]
  • 15. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; 18(4)[DOI]
  • 16. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; [DOI]
  • 17. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006; 1(2): 256-62[DOI][PubMed]
  • 18. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006; 1(5): 940-51[DOI][PubMed]
  • 19. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005; 28(9): 2106-12[PubMed]
  • 20. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005; 68(6): 2829-36[DOI][PubMed]
  • 21. Sica DA. The risks and benefits of therapy with aldosterone receptor antagonist therapy. Curr Drug Saf. 2007; 2(1): 71-7[PubMed]
  • 22. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005; 46(1): 45-51[PubMed]
  • 23. Epstein M. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertension. 2002; 15(4)[DOI]
  • 24. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4(3): 542-51[DOI][PubMed]
  • 25. Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol. 2002; 22(5): 399-406[PubMed]
  • 26. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992; 41(2): 326-33[PubMed]
  • 27. Gavras H, Brunner HR, Laragh JH, Vaughan EJ, Koss M, Cote LJ, et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res. 1975; 36(2): 300-9[PubMed]
  • 28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851-60[DOI][PubMed]
  • 29. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15): 939-45[DOI][PubMed]
  • 30. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005; 18(1): 44-9[DOI][PubMed]
  • 31. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001; 345(12): 925-6[DOI][PubMed]
  • 32. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008; 51(2): 199-211[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments